NOVACEA
As of January 30, 2009, Novacea, Inc. was acquired by Transcept Pharmaceuticals, Inc., in a reverse merger transaction. Novacea, Inc., a biopharmaceutical company, focuses on in-licensing, developing, and commercializing therapies for the treatment of cancer. The companyรขโฌโขs product candidates include Asentar, which is in Phase III clinical trial for the treatment of androgen-independent prostate cancer and in Phase II clinical trial for the treatment of advanced pancreatic cancer; and AQ4N... , a hypoxia-activated prodrug in Phase Ib/IIa clinical trial for the treatment of glioblastoma multiforme. It has license and collaboration agreements with Aventis Pharmaceuticals, Inc.; Oregon Health & Science University; University of Pittsburgh; KuDOS Pharmaceuticals Limited; and BTG International Limited. The company was founded in 2001 and is headquartered in South San Francisco, California.
NOVACEA
Industry:
Biotechnology Health Care Medical
Founded:
2001-01-01
Address:
San Francisco, California, United States
Country:
United States
Total Employee:
11+
Status:
Active
Total Funding:
71 M USD
Current Employees Featured
Investors List
ProQuest Investments
ProQuest Investments investment in Series C - Novacea
Sofinnova Investments
Sofinnova Investments investment in Series C - Novacea
New Enterprise Associates
New Enterprise Associates investment in Series C - Novacea
Domain Associates
Domain Associates investment in Series C - Novacea
Versant Ventures
Versant Ventures investment in Series C - Novacea
Apax Partners
Apax Partners investment in Series C - Novacea
Sofinnova Investments
Sofinnova Investments investment in Series B - Novacea
New Enterprise Associates
New Enterprise Associates investment in Series B - Novacea
Versant Ventures
Versant Ventures investment in Series B - Novacea
Domain Associates
Domain Associates investment in Series B - Novacea